 Zynerba Pharmaceuticals Inc told investors that an article in the Journal of the American Medical Association JAMA Network Open had described the results of the companys open-label Phase 2 BELIEVE study as positive. This is an open label study assessing the safety and efficacy of Zygel ZYN002 as a transdermal gel for children and adolescents with developmental and epileptic encephalopathy DEE. 